Palliative Hepatectomy for Advanced Hepatocellular Carcinoma with Multiple Metastases: A Case Report.
- Author:
Jae myeong LEE
1
;
Kwang Min PARK
;
Julian CHOI
;
Sang Hoon CHON
;
Dae Wook HWANG
;
Young Joo LEE
Author Information
1. Department of Surgery, Ajou University School of Medicine, Division of Hepato-Biliary & Pancreas Surgery, Korea.
- Publication Type:Case Report
- Keywords:
Hepatocellular carcinoma;
Metastasis;
Palliative treatment;
Hepatectomy
- MeSH:
Adenoma;
Adrenal Glands;
Aged;
Benzeneacetamides;
Biopsy;
Carcinoma, Hepatocellular;
Cause of Death;
Follow-Up Studies;
Hepatectomy;
Humans;
Liver;
Liver Cirrhosis;
Lung;
Neoplasm Metastasis;
Niacinamide;
Palliative Care;
Phenylurea Compounds;
Piperidones;
Recurrence
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2009;13(4):295-300
- CountryRepublic of Korea
- Language:English
-
Abstract:
Non-surgical treatment is usually performed for the cases of hepatocellular carcinoma (HCC) that are not suitable for curative treatment, such as those cases with a large tumor size with an insufficient hepatic remnant after resection, those cases with extensive and multifocal bilobar tumors or those cases with extrahepatic metastases of the disease. However, in this case report we present a case of palliative hepatectomy for treating advanced HCC with multiple metastases and the patient has had an excellent 1-year follow-up outcome. A 71-year-old man was referred to our hospital and the imaging studies showed a 10 cm mass in the right liver, with multiple variable sized masses in both lungs and a 1 cm nodule in the left adrenal gland. A lung biopsy revealed HCC; therefore, the working diagnosis was HCC with multiple lung metastases and a left adrenal gland adenoma or metastasis. We expected the cause of death would be deterioration of the hepatic function as the liver mass increased in size. Therefore, we performed a palliative right trisectionectomy for the primary liver mass. After recovery from the hepatectomy, the patient was managed with sorafenib. During the 1-year follow-up period after palliative hepatectomy, the patient is still alive with a good general performance status and no evidence of intrahepatic recurrence, even though there has been an aggravation of the lung metastases in size and number, and a slight increase in the size of the left adrenal gland. We suggest that in highly selected patients with advanced HCC and multiple extrahepatic metastases, and especially in the cases involving a large HCC with mild liver cirrhosis and a good general performance status, an aggressive treatment strategy with palliative hepatectomy can be an optional treatment modality to improve the overall survival.
